Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2)

MLA

Kim A. Papp, et al. “Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2).” Journal of Drugs in Dermatology : JDD, vol. 20, no. 8, Aug. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....29027e55cc27297db094cedf37b211ec&authtype=sso&custid=ns315887.

APA

Kim A. Papp, Kyoungah See, Bruce W Konicek, Sascha Gerdes, William J Eastman, Craig L. Leonardi, H. Elmaraghy, Missy McKean-Matthews, & Heidi Crane. (2021). Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2). Journal of Drugs in Dermatology : JDD, 20(8).

Chicago

Kim A. Papp, Kyoungah See, Bruce W Konicek, Sascha Gerdes, William J Eastman, Craig L. Leonardi, H. Elmaraghy, Missy McKean-Matthews, and Heidi Crane. 2021. “Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2).” Journal of Drugs in Dermatology : JDD 20 (8). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....29027e55cc27297db094cedf37b211ec&authtype=sso&custid=ns315887.